DEST News and Press, Destination Maternity Corporation

(NewsDirect) Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) CEO Neil Clark speaks to Proactive after releasing fresh data from the update from a research collaboration into a novel biotherapeutic treatment for COVID-19 and influenza. Clark says that the project has already delivered "more than ...

(NewsDirect) Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) CEO Neil Clark speaks to Thomas Warner from Proactive after releasing the clinical-stage biotechnology company's full year results for 2022. Clark says that Destiny Pharma is focused on finding a partner for its lead asset, XF-73, ...

(NewsDirect) Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) chief scientific officer Bill Love speaks to Proactive after results from a study into its C. Difficile treatment platform NTCD-M3 were published in the Microbiology Spectrum journal. Love explains what makes the platform so promis...

(NewsDirect) Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) chief executive Neil Clark speaks to Thomas Warner from Proactive after publishing research about the company's new nasal gel, called XF-73, in the US journal 'Infection Control & Hospital Epidemiology'. Clark explains more abo...

(NewsDirect) Destiny Pharma PLC (AIM:DEST) chief executive Neil Clark updates Proactive's Thomas Warner on the latest news from the clinical-stage biotech company. The update follows the announcement that Destiny has reached a collaboration and co-development agreement for its phase 3...

Implements Path Forward to Enhance Profitability and Continue Its Ongoing Sale Process Destination Maternity Corporation (NASDAQ: DEST) (“Destination Maternity” or the “Company”), the premier national retailer for maternity apparel and accessories, today ann...

Destination Maternity Corporation (DEST) Q2 2019 Earnings Conference Call September 17, 2019 10:00 ET Company Participants David Helkey - CFO & COO Lisa Gavales - Chair of our Interim Office of CEO Conference Call Participants Presentation Operator Good day, ladie...

Destination Maternity ( DEST -13.2% ) reported Q2 revenue decrease of 11.9% Y/Y to $84.9M, impacted by the net closure of 6 owned locations and 55 leased lease locations and decrease in comparable sales. More news on: Destination Maternity Corporation, Earnings news and commentary, Stock...

Destination Maternity (NASDAQ: DEST ): Q2 Non-GAAP EPS of -$0.20; GAAP EPS of -$0.25. More news on: Destination Maternity Corporation, Earnings news and commentary, Consumer stocks news, , Read more ...

- Operating loss of $2.2 million versus $2.8 million in prior year period - Adjusted EBITDA before other charges of $2.0 million versus $4.0 million in prior year period - Gross Profit Margins of 51.4% versus 51.7% in prior year period - Selling, General and Administrative expenses ...